Clinical

Patients with advanced glaucoma had better outcomes when treated with trabeculectomy rather than using medication first.

Wastewater SARS-CoV-2 levels correlated with hospital COVID-19 cases, supporting targeted screening of asymptomatic patients.

The BCBSNC Foundation's focus on access to care, health through food, and youth mental health aligns with broader national health trends.

Newly FDA-approved doravirine/Islatravir maintained HIV suppression in phase 3 trials with comparable safety and minimal metabolic effects.

CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization challenges remain, per Sylvester Homsy, MD.

Behavioral text nudges outperformed nurse calls, boosting FIT completion by 9 percentage points at an FQHC while saving staff time.

Multidisciplinary collaboration is essential in managing high-risk CSCC, helping clinicians overcome logistical barriers to deliver coordinated, individualized care.

VESALIUS-CV shows that evolocumab delivers a 31% relative risk reduction in major cardiovascular events in high-risk diabetic patients without established atherosclerosis—making a compelling case for intensive LDL lowering well before a first event.

Beyond standard risk scores, the guideline highlights key risk enhancers—including lipoprotein(a), inflammation markers, and women's health factors—and elevates coronary artery calcium scoring as a Class I tool for resolving uncertainty in primary prevention.

Long-acting CAB+RPV may maintain efficacy even with delayed injections, offering real-world flexibility.

Neoadjuvant immunotherapy is expanding treatment options in CSCC by shrinking complex tumors, improving surgical outcomes, and potentially enhancing long-term disease control.

A 2-week sleep/light intervention shifted teens’ circadian timing earlier, increasing weeknight sleep by about 47 minutes in a randomized trial.

OCM showed no increased likelihood of starting systemic therapy in patients with newly diagnosed cancers, despite gains in poor-prognosis cases.

A case study shows positive outcomes following allogeneic stem cell transplantation in a patient with highly refractory MM and therapy-related MDS/AML.

The weekly anifrolumab autoinjector for systemic lupus erythematosus enables at-home use and improves convenience on top of standard therapy.

A French real-world study of 282 patients with CLL identified 2 distinct treatment profiles shaped by age, genetics, and logistics—not trial data alone.

Phase 3 TETON-1 trial shows inhaled treprostinil improves FVC in IPF, signaling a potential new antifibrotic option.

Explore 5 FAQs on CDC opioid guidelines, including dosing, tapering, monitoring, and managed care strategies to reduce overdose risk.

Off-the-shelf cema-cel clears MRD at more than triple the rate of observation alone—and may propel a shift to frontline use of CAR T-cell therapy when relapse is hard to detect.

Nicole A. Caffiero, PharmD, MBA, BCACP, concluded AMCP 2026 by highlighting key themes shaping the specialty drug market.

Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment.

A faster, cheaper alternative to karyotyping, DNA index testing shows near-perfect accuracy for detecting high hyperdiploidy in pediatric patients with leukemia.

FDA approves doravirine/islatravir, a once-daily, 2-drug, single-tablet HIV regimen showing noninferior efficacy to standard therapies in suppressed adults.

PFAS exposure, especially PFDA, was linked to higher nonmelanoma skin cancer odds, with stronger effects observed in older adults.

For the first time, the 2026 ACC/AHA guideline provides strong, evidence-based recommendations for patients who cannot tolerate statins—a group historically underserved by prior guidance. Outcome data now support bempedoic acid (from the CLEAR trial), PCSK9 monoclonal antibodies, ezetimibe, and inclisiran as viable alternatives. Rather than defaulting to high-intensity statin doses, clinicians can consider combination strategies such as a moderate-intensity statin paired with ezetimibe—a pairing shown in the RACING trial to match the cardiovascular event reduction of high-intensity monotherapy while improving tolerability and LDL goal achievement. The "rule of sixes"—where doubling a statin dose yields only an additional 6% LDL reduction versus 18% from adding ezetimibe—further reinforces early combination thinking.